Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 13
Submit an article Journal homepage
79
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Hypereosinophilic syndrome with leptomeningeal involvement: a not-so-classical case report of classical Hodgkin Lymphoma

George Mellgarda Department of Medicine, NewYork Presbyterian – Columbia University Irving Medical Center, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8649-9855View further author information
ORCID Icon,
Elina Stoffela Department of Medicine, NewYork Presbyterian – Columbia University Irving Medical Center, New York, NY, USAView further author information
,
Alissa Michelb Department of Hematology and Oncology, NewYork Presbyterian – Columbia University Irving Medical Center, New York, NY, USAView further author information
,
Fatima Iqbalc Department of Pathology, NewYork Presbyterian – Columbia University Irving Medical Center, New York, NY, USAView further author information
,
Anthony Provenzanob Department of Hematology and Oncology, NewYork Presbyterian – Columbia University Irving Medical Center, New York, NY, USAView further author information
,
Imo J. Akpanb Department of Hematology and Oncology, NewYork Presbyterian – Columbia University Irving Medical Center, New York, NY, USAView further author information
,
Jennifer Amengualb Department of Hematology and Oncology, NewYork Presbyterian – Columbia University Irving Medical Center, New York, NY, USAView further author information
&
Barbara Prob Department of Hematology and Oncology, NewYork Presbyterian – Columbia University Irving Medical Center, New York, NY, USAView further author information
 show all
Pages 2208-2213 | Received 19 Jul 2023, Accepted 16 Aug 2023, Published online: 28 Aug 2023

References

  • Crane MM, Chang CM, Kobayashi MG, et al. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol. 2010;126(1):179–181. doi:10.1016/j.jaci.2010.03.035
  • Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment Mayo Clinic Proceedings. Elsevier. 2010; 158–164. doi:10.4065/mcp.2009.0503
  • American Cancer Society, 2023.
  • Kaseb H, Babiker HM. Hodgkin lymphoma. 2018.
  • Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis. 2001;5(1):191–218. doi:10.1016/s1089-3261(05)70161-6
  • American Cancer Society. Key Statistics for Hodgkin Lymphoma. 2023. https://www.cancer.org/cancer/types/hodgkin-lymphoma/about/key-statistics.html
  • Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV hodgkin’s lymphoma. N Engl J Med. 2022;387(4):310–320. doi:10.1056/NEJMoa2206125
  • Helbig G, Klion AD. Hypereosinophilic syndromes–an enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment. Blood Rev. 2021;49:100809. doi:10.1016/j.blre.2021.100809
  • Lee D, Ahn T-B. Central nervous system involvement of hypereosinophilic syndrome: a report of 10 cases and a literature review. J Neurol Sci. 2014;347(1-2):281–287. doi:10.1016/j.jns.2014.10.023
  • Hollister D, Clements M, Coleman M, et al. Eosinophilic meningitis in hodgkin’s disease: report of a case and review of the literature. Arch Intern Med. 1983;143(3):590–592. doi:10.1001/archinte.1983.00350030204039
  • Strayer DR, Bender RA. Eosinophilic meningitis complicating hodgkin’s disease. A report of a case and review of the literature. Cancer. 1977;40(1):406–409. doi:10.1002/1097-0142(197707)40:1<406::AID-CNCR2820400158>3.0.CO;2-N
  • Re D, Fuchs M, Schober T, et al. CNS involvement in hodgkin’s lymphoma. J Clin Oncol. 2007;25(21):3182–3182. doi:10.1200/jco.2007.12.5088
  • Gerstner ER, Abrey LE, Schiff D, et al. CNS hodgkin lymphoma. Blood. 2008;112(5):1658–1661. doi:10.1182/blood-2008-04-151563
  • Yasenchak CA, Bordoni R, Patel-Donnelly D, et al. Brentuximab vedotin in frontline therapy of hodgkin lymphoma in patients with significant comorbidities ineligible for standard chemotherapy (SGN35-015 part E). Blood. 2022;140(Supplement 1):3685–3686. doi:10.1182/blood-2022-156567
  • Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical hodgkin lymphoma. J Clin Oncol. 2018;36(30):3015–3022. doi:10.1200/JCO.2018.79.0139

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.